Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (TURANDOT II)

Trial Profile

A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (TURANDOT II)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2019

At a glance

  • Drugs SHP 647 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Acronyms TURANDOT-II
  • Sponsors Pfizer; Shire
  • Most Recent Events

    • 24 Oct 2018 Results assessing long-term safety and tolerability of SHP647 presented at the 26th United European Gastroenterology Week.
    • 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
    • 21 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top